Menu
GeneBe

rs140387675

Variant summary

Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2

The NM_000057.4(BLM):c.3427G>A(p.Glu1143Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000905 in 1,613,766 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000093 ( 0 hom. )

Consequence

BLM
NM_000057.4 missense

Scores

5
8
6

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:10B:1

Conservation

PhyloP100: 9.19
Variant links:
Genes affected
BLM (HGNC:1058): (BLM RecQ like helicase) The Bloom syndrome is an autosomal recessive disorder characterized by growth deficiency, microcephaly and immunodeficiency among others. It is caused by homozygous or compound heterozygous mutation in the gene encoding DNA helicase RecQ protein on chromosome 15q26. This Bloom-associated helicase unwinds a variety of DNA substrates including Holliday junction, and is involved in several pathways contributing to the maintenance of genome stability. Identification of pathogenic Bloom variants is required for heterozygote testing in at-risk families. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
BLMNM_000057.4 linkuse as main transcriptc.3427G>A p.Glu1143Lys missense_variant 18/22 ENST00000355112.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
BLMENST00000355112.8 linkuse as main transcriptc.3427G>A p.Glu1143Lys missense_variant 18/221 NM_000057.4 P2

Frequencies

GnomAD3 genomes
AF:
0.0000657
AC:
10
AN:
152122
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000655
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000103
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000107
AC:
27
AN:
251310
Hom.:
0
AF XY:
0.0000957
AC XY:
13
AN XY:
135828
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000163
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000185
Gnomad OTH exome
AF:
0.000326
GnomAD4 exome
AF:
0.0000930
AC:
136
AN:
1461644
Hom.:
0
Cov.:
31
AF XY:
0.0000839
AC XY:
61
AN XY:
727076
show subpopulations
Gnomad4 AFR exome
AF:
0.0000896
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.000101
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000110
Gnomad4 OTH exome
AF:
0.0000828
GnomAD4 genome
AF:
0.0000657
AC:
10
AN:
152122
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74300
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.0000655
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.000193
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000103
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000167
Hom.:
0
Bravo
AF:
0.0000982
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.000107
AC:
13
EpiCase
AF:
0.000327
EpiControl
AF:
0.000119

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:10Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Bloom syndrome Uncertain:5
Uncertain significance, no assertion criteria providedclinical testingNatera, Inc.Jun 20, 2018- -
Uncertain significance, criteria provided, single submitterclinical testingGenome-Nilou LabJul 14, 2021- -
Uncertain significance, criteria provided, single submitterclinical testingInvitaeOct 15, 2022This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1143 of the BLM protein (p.Glu1143Lys). This variant is present in population databases (rs140387675, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of BLM-related conditions (PMID: 30262796). ClinVar contains an entry for this variant (Variation ID: 127499). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BLM protein function. Experimental studies have shown that this missense change does not substantially affect BLM function (PMID: 23129629). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingRevvity Omics, RevvityNov 12, 2019- -
Uncertain significance, criteria provided, single submitterclinical testingMendelicsJul 02, 2018- -
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJun 01, 2018- -
Likely benign, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoFeb 11, 2023- -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxApr 29, 2022In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate: sensitivity to hydroxyurea similar to wildtype, suggesting no significant impact on helicase activity (Tsaousis et al., 2019); Observed in individuals with a personal or family history including colorectal and breast and/or ovarian cancer (Quezada Urban et al., 2018; Tsaousis et al., 2019; Belhadj et al., 2020); This variant is associated with the following publications: (PMID: 32449991, 23129629, 30262796, 31159747) -
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsApr 26, 2023The p.E1143K variant (also known as c.3427G>A), located in coding exon 17 of the BLM gene, results from a G to A substitution at nucleotide position 3427. The glutamic acid at codon 1143 is replaced by lysine, an amino acid with similar properties. This alteration did not show hypersensitivity to the DNA damaging agent hydroxyurea, as compared to the wild-type allele, in a humanized yeast model (Mirzaei H et al. Proc. Natl. Acad. Sci. U.S.A. 2012 Nov;109:19357-62). This alteration has been reported in an individual with a personal history of five primary malignant cancers and a family history consistent with Li Fraumeni syndrome, who was identified to carry TP53 p.R175H (Zampiga V et al. Int J Biol Markers, 2016 Dec;31:e461-e465). This variant has also been reported in multiple cohorts undergoing evaluation for inherited cancer predisposition (DeRycke MS et al. Mol Genet Genomic Med, 2017 Sep;5:553-569; Quezada Urban R et al. Cancers (Basel), 2018 Sep;10:; Tsaousis GN et al. BMC Cancer, 2019 Jun;19:535; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Uncertain significance, criteria provided, single submitterclinical testingGeneKor MSAAug 01, 2018- -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoMay 26, 2021DNA sequence analysis of the BLM gene demonstrated a sequence change, c.3427G>A, in exon 18 that results in an amino acid change, p.Glu1143Lys. This sequence change has been described in gnomAD with a frequency of 0.02% in the East Asian sub-population (dbSNP rs140387675). The p.Glu1143Lys change affects a moderately conserved amino acid residue located in a domain of the BLM protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Glu1143Lys substitution. This sequence change does not appear to have been previously described in patients with BLM-related disorders. Due to the lack of sufficient evidences, the clinical significance of the p.Glu1143Lys change remains unknown at this time. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.78
BayesDel_addAF
Benign
-0.13
T
BayesDel_noAF
Benign
-0.15
Cadd
Pathogenic
27
Dann
Pathogenic
1.0
DEOGEN2
Benign
0.38
T
Eigen
Uncertain
0.64
Eigen_PC
Pathogenic
0.69
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.97
D
M_CAP
Benign
0.045
D
MetaRNN
Uncertain
0.66
D
MetaSVM
Benign
-0.68
T
MutationAssessor
Pathogenic
3.7
H
MutationTaster
Benign
1.0
D;D
PrimateAI
Uncertain
0.59
T
PROVEAN
Uncertain
-3.6
D
REVEL
Uncertain
0.34
Sift
Uncertain
0.0050
D
Sift4G
Uncertain
0.0080
D
Polyphen
0.75
P
Vest4
0.72
MVP
0.82
MPC
0.51
ClinPred
0.93
D
GERP RS
5.7
Varity_R
0.95
gMVP
0.66

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs140387675; hg19: chr15-91346819; COSMIC: COSV61923645; API